

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
<b>Maraldo David R.</b>			<b>5/1/2026</b>		<b>Merck &amp; Co., Inc. [MRK]</b>		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<b>126 EAST LINCOLN AVENUE</b>			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>EVP &amp; Pres. MMD /</b>				
(Street)			5. If Amendment, Date Original Filed(MM/DD/YYYY)		6. Individual or Joint/Group Filing(Check Applicable Line)		
<b>RAHWAY NEW JERSEY 07065</b>					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip/Postal Code)							
<b>UNITED STATES</b>							
(Country)							

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<b>Common Stock</b>	<b>17,819.434</b>	<b>D</b>	
<b>Common Stock - 401(k) Plan</b>	<b>8,359.14</b>	<b>I</b>	<b>By 401 (k)</b>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<b>Restricted Stock Unit</b>	<b>5/2/2024 <sup>(1)</sup></b>	<b>5/2/2026</b>	<b>Common Stock</b>	<b>552</b>	<b><sup>(2)</sup></b>	<b>D</b>	
<b>Restricted Stock Unit</b>	<b>4/30/2025 <sup>(3)</sup></b>	<b>4/30/2027</b>	<b>Common Stock</b>	<b>581</b>	<b><sup>(2)</sup></b>	<b>D</b>	
<b>Restricted Stock Unit</b>	<b>4/29/2026 <sup>(4)</sup></b>	<b>4/29/2028</b>	<b>Common Stock</b>	<b>2,361</b>	<b><sup>(2)</sup></b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>5/4/2022 <sup>(5)</sup></b>	<b>5/3/2031</b>	<b>Common Stock</b>	<b>9,465</b>	<b>\$73.73</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>5/3/2023 <sup>(6)</sup></b>	<b>5/2/2032</b>	<b>Common Stock</b>	<b>9,709</b>	<b>\$87.1</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>5/2/2024 <sup>(7)</sup></b>	<b>5/1/2033</b>	<b>Common Stock</b>	<b>8,990</b>	<b>\$117.89</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>4/30/2025 <sup>(8)</sup></b>	<b>4/29/2034</b>	<b>Common Stock</b>	<b>8,789</b>	<b>\$129.22</b>	<b>D</b>	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<b>Stock Option (Right to Buy)</b>	<b>4/29/2026</b> <sup>(9)</sup>	<b>4/28/2035</b>	<b>Common Stock</b>	<b>8,060</b>	<b>\$84.71</b>	<b>D</b>	

**Explanation of Responses:**

- (1) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025, and 5/2/2026.
- (2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
- (3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026, and 4/30/2027.
- (4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
- (5) The options became exercisable in equal installments in on 5/4/2022, 5/4/2023, and 5/4/2024.
- (6) The options became exercisable in equal installments in on 5/5/2024, 5/5/2025, and 5/5/2026.
- (7) The options vest and become exercisable in equal installments on 5/2/2024, 5/2/2025, and 5/2/2026.
- (8) The options vest and become exercisable in equal installments on 4/30/2025, 4/30/2026, and 4/30/2027.
- (9) The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>Maraldo David R. 126 EAST LINCOLN AVENUE RAHWAY NEW JERSEY 07065 UNITED STATES</b>			<b>EVP &amp; Pres. MMD</b>	

**Signatures**

/s/ Kelly E. W. Grez as Attorney-in-Fact for David Maraldo

5/4/2026

<sup>\*\*\*</sup>Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

\* Form 3: SEC 1473 (03-26).